In line with these findings, our prior research demonstrated that nanomedicines comprising C-SLN/ASO-IGFL2-AS1 complexes and CS-EGCG/circSPIRE1 plasmid complexes specifically target renal cancer in vivo [50, 51]. Here, IGFL2 is linked to renal carcinoma.